Massachusett-based Stoke Therapeutics (STOK) is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024.In t ...